Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

What happened: Biomea Fusion (Nasdaq: BMEA) reported Phase 1 GLP-131 results for BMF-650, an investigational oral small molecule GLP-1 receptor agonist, showing weight reduction across five MAD cohorts over four weeks. Key numbers: Mean Day 29 weight reduction 1.5% to 3.2% in Cohorts 1-4 versus 0.1% for pooled placebo. Why it matters: The company said the findings provide early evidence of clinical activity and tolerability, and may support testing a no titration regimen. Biomea said its primary development focus remains menin inhibition with icovamenib in type 1 and type 2 diabetes. Coverage: 3 outlets in 24h

Biomea Fusion (Nasdaq: BMEA) reported Phase 1 GLP-131 results for BMF-650, an investigational oral small molecule GLP-1 receptor agonist, showing weight reduction across five MAD cohorts over four weeks.

The company said the findings provide early evidence of clinical activity and tolerability, and may support testing a no titration regimen. Biomea said its primary development focus remains menin inhibition with icovamenib in type 1 and type 2 diabetes.